Bellvitge Biomedical Research Institute (IDIBELL) Spain
Research
Date range: 1 December 2020 - 30 November 2021
Region: Global
Subject/journal group: All
The table to the right includes counts of all research outputs for Bellvitge Biomedical Research Institute (IDIBELL) published between 1 December 2020 - 30 November 2021 which are tracked by the Nature Index.
Hover over the donut graph to view the Share for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
Count | Share |
---|---|
37 | 4.30 |
Outputs by subject (Share)
Subject | Count | Share |
---|---|---|
Life Sciences | 35 | 4.12 |
Physical Sciences | 2 | 0.13 |
Chemistry | 1 | 0.09 |
Share output for the past 5 years
2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|
6.27 | 4.41 | 4.38 | 5.53 | 3.15 |
Compare Bellvitge Biomedical Research Institute (IDIBELL) with other institutions
Collaboration
Date range: 1 December 2020 - 30 November 2021
International vs. domestic collaboration by Share
- 49.69% Domestic
- 50.31% International
Hover over the graph to view the percentage of collaboration.
Top 10 domestic collaborators with Bellvitge Biomedical Research Institute (IDIBELL) by Share (71 total)
-
Bellvitge Biomedical Research Institute (IDIBELL) and University of Barcelona (UB)
(7.66)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Catalan Health Institute (ICS)
(7.11)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Catalan Institute of Oncology (ICO)
(5.54)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Institute of Health Carlos III (ISCIII)
(4.43)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Josep Carreras Leukaemia Research Institute (IJC)
(2.56)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Barcelona Institute of Science and Technology (BIST)
(2.12)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Spanish National Research Council (CSIC)
(1.86)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Catalan Institution for Research and Advanced Studies (ICREA)
(1.62)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Spanish National Cancer Research Centre (CNIO)
(1.46)
-
Bellvitge Biomedical Research Institute (IDIBELL) and August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
(0.84)
Top 10 international collaborators with Bellvitge Biomedical Research Institute (IDIBELL) by Share (352 total)
-
Bellvitge Biomedical Research Institute (IDIBELL) and National Institute for Health and Medical Research (INSERM)
(1.09)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Helmholtz Association of German Research Centres
(1.04)
-
Bellvitge Biomedical Research Institute (IDIBELL) and French National Centre for Scientific Research (CNRS)
(1.00)
-
Bellvitge Biomedical Research Institute (IDIBELL) and University of Toronto (U of T)
(0.93)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Mount Sinai Health System (MSHS)
(0.90)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Amsterdam UMC
(0.75)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Columbia University in the City of New York (CU)
(0.74)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Duke University
(0.74)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Harvard University
(0.67)
-
Bellvitge Biomedical Research Institute (IDIBELL) and Université Libre de Bruxelles (ULB)
(0.66)
Relationships
Bellvitge Biomedical Research Institute (IDIBELL)
- Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL
- Molecular Mechanisms and Experimental Therapy in Oncology Program, IDIBELL
- Oncobell Program, IDIBELL
Partner Institutions
Bellvitge Biomedical Research Institute (IDIBELL) is a research collaboration whose article contributions are accrued to its participating partner institutions below.

Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.